Back to Search Start Over

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.

Authors :
MacGregor, E Anne
Komori, Mika
Krege, John Henry
Baygani, Simin
Vincent, Maurice
Pavlovic, Jelena
Igarashi, Hisaka
Source :
Cephalalgia. Dec2022, Vol. 42 Issue 14, p1467-1475. 9p.
Publication Year :
2022

Abstract

<bold>Background: </bold>Perimenstrual migraine attacks in women with menstrual migraine is difficult to treat. This post-hoc analysis evaluated the efficacy of lasmiditan, a high affinity and selective 5-HT1F receptor agonist, for perimenstrual attacks.<bold>Methods: </bold>Patients from two randomized, double-blind, placebo-controlled clinical trials (MONONOFU and CENTURION) were instructed to treat an attack with a single dose of study medication within four hours of pain onset. After dosing, the proportion of patients who achieved freedom from migraine-related head pain, most bothersome symptom, and disability was reported at baseline up to 48 hours after dose and pooled data were evaluated.<bold>Results: </bold>A total of 303 patients (MONONOFU N = 78; CENTURION N = 225) treated perimenstrual migraine attacks with lasmiditan 50 mg (N = 24), 100 mg (N = 90), 200 mg (N = 110), and placebo (N = 79). More patients achieved migraine-related head pain freedom with lasmiditan 200 mg versus placebo at all time points assessed. At 2 hours, 33.6% of patients in the 200-mg group (p < 0.001), and 16.7% of patients in the 100-mg (p = 0.11) and 50-mg (p = 0.19) groups were pain free, compared with 7.6% in the placebo group.<bold>Conclusions: </bold>Lasmiditan treatment of perimenstrual migraine attacks was associated with freedom from migraine-related head pain at two hours, early onset of efficacy, and sustained efficacy.Clinical Trial registration: NCT03962738 and NCT03670810. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
*MIGRAINE
*HEADACHE
*MIGRAINE aura

Details

Language :
English
ISSN :
03331024
Volume :
42
Issue :
14
Database :
Academic Search Index
Journal :
Cephalalgia
Publication Type :
Academic Journal
Accession number :
160404168
Full Text :
https://doi.org/10.1177/03331024221118929